The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis

被引:25
作者
Alimohammadian, MH
Khamesipour, A
Darabi, H
Firooz, A
Malekzadeh, S
Bahonar, A
Dowlati, Y
Modabber, F
机构
[1] Infect Dis Res Inst, Seattle, WA 98104 USA
[2] Pasteur Inst Iran, Dept Immunol, Tehran, Iran
[3] Univ Med Sci, Ctr Res & Training Skin Dis & Leprosy, Tehran 14166, Iran
[4] Isfahan Univ Med Sci, Hlth Ctr Aran Bidgol, Esfahan, Iran
关键词
leishmaniasis; BCG; vaccine;
D O I
10.1016/S0264-410X(02)00458-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To determine if BCG was required in booster injections for autoclaved Leishmania major (ALM) vaccine, 75 volunteers with no response to leishmanin were injected double-blind and randomly with either ALM + BCG or BCG alone for the first injection and boosted either with ALM + BCG, ALM or BCG alone for the second and third. Addition of BCG to the boosters significantly increased the frequency and the magnitude of leishmanin skin tests (LSTs); however, there was no difference in proliferative and IFN-gamma responses (a month and a year later). Three injections of BCG produced no observable adverse reaction; hence BCG could be used in booster injections to increase the protective potential of this candidate vaccine. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:174 / 180
页数:7
相关论文
共 22 条
[1]   Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection [J].
Ajdary, S ;
Alimohammadian, MH ;
Eslami, MB ;
Kemp, K ;
Kharazmi, A .
INFECTION AND IMMUNITY, 2000, 68 (04) :1760-1764
[2]  
Alimohammadian MH, 1993, MED J IRAN, V93, P23
[3]   CONTROLLED FIELD TRIALS OF A VACCINE AGAINST NEW-WORLD CUTANEOUS LEISHMANIASIS [J].
ANTUNES, CM ;
MAYRINK, W ;
MAGALHAES, PA ;
COSTA, CA ;
MELO, MN ;
DIAS, M ;
MICHALICK, MSM ;
WILLIAMS, P ;
LIMA, AO ;
VIEIRA, JBF ;
SCHETTINI, APM .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1986, 15 (04) :572-580
[4]   Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers [J].
Bahar, K ;
Dowlati, Y ;
Shidani, B ;
Alimohammadian, MH ;
Khamesipour, A ;
Ehsasi, S ;
HashemiFesharki, R ;
AleAgha, S ;
Modabber, F .
CLINICS IN DERMATOLOGY, 1996, 14 (05) :489-495
[5]   IMMUNE-RESPONSE IN HEALTHY-VOLUNTEERS VACCINATED WITH KILLED LEISHMANIAL PROMASTIGOTES PLUS BCG .1. SKIN-TEST REACTIVITY, T-CELL PROLIFERATION AND INTERFERON-GAMMA PRODUCTION [J].
CASTES, M ;
BLACKWELL, J ;
TRUJILLO, D ;
FORMICA, S ;
CABRERA, M ;
ZORRILLA, G ;
RODAS, A ;
CASTELLANOS, PL ;
CONVIT, J .
VACCINE, 1994, 12 (11) :1041-1051
[6]   IMMUNOTHERAPY OF LOCALIZED, INTERMEDIATE, AND DIFFUSE FORMS OF AMERICAN CUTANEOUS LEISHMANIASIS [J].
CONVIT, J ;
CASTELLANOS, PL ;
ULRICH, M ;
CASTES, M ;
RONDON, A ;
PINARDI, ME ;
RODRIQUEZ, N ;
BLOOM, BR ;
FORMICA, S ;
VALECILLOS, L ;
BRETANA, A .
JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (01) :104-115
[7]   Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis [J].
De Luca, PM ;
Mayrink, W ;
Alves, CR ;
Coutinho, SG ;
Oliveira, MP ;
Bertho, AL ;
Toledo, VP ;
Costa, CA ;
Genaro, O ;
Mendonça, SCF .
VACCINE, 1999, 17 (9-10) :1179-1185
[8]   Stepwise safety trial of a killed Leishmania vaccine in Iran [J].
Dowlati, Y ;
Ehsasi, S ;
Shidani, B ;
Bahar, K .
CLINICS IN DERMATOLOGY, 1996, 14 (05) :497-502
[9]  
HASHEMIFESHARAK.R, 1998, IRANIAN J MED SCI, V23, P74
[10]  
Kenney RT, 1999, J IMMUNOL, V163, P4481